CA2527094A1 - Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders - Google Patents

Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders Download PDF

Info

Publication number
CA2527094A1
CA2527094A1 CA002527094A CA2527094A CA2527094A1 CA 2527094 A1 CA2527094 A1 CA 2527094A1 CA 002527094 A CA002527094 A CA 002527094A CA 2527094 A CA2527094 A CA 2527094A CA 2527094 A1 CA2527094 A1 CA 2527094A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl group
mip synthase
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002527094A
Other languages
English (en)
French (fr)
Inventor
Meir Bialer
Boris Yagen
Haim Belmaker
Galila Agam
Galit Shaltiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ben Gurion University of the Negev Research and Development Authority Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2527094A1 publication Critical patent/CA2527094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002527094A 2003-05-29 2004-05-27 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders Abandoned CA2527094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15620303A IL156203A0 (en) 2003-05-29 2003-05-29 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
IL156203 2003-05-29
PCT/IL2004/000455 WO2004105746A1 (en) 2003-05-29 2004-05-27 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders

Publications (1)

Publication Number Publication Date
CA2527094A1 true CA2527094A1 (en) 2004-12-09

Family

ID=32587598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002527094A Abandoned CA2527094A1 (en) 2003-05-29 2004-05-27 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders

Country Status (8)

Country Link
US (1) US20100048721A2 (enExample)
EP (1) EP1626710B1 (enExample)
JP (1) JP2007500205A (enExample)
AT (1) ATE409469T1 (enExample)
CA (1) CA2527094A1 (enExample)
DE (1) DE602004016841D1 (enExample)
IL (2) IL156203A0 (enExample)
WO (1) WO2004105746A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157751A0 (en) 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
US20060004098A1 (en) 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
CN100426897C (zh) 2005-01-12 2008-10-15 华为技术有限公司 分体式基站系统及其组网方法和基带单元
CN102198121B (zh) * 2011-04-08 2012-05-23 广东药学院 2,2,3,3-四甲基环丙酰硫脲在制备抗肿瘤药物中的应用
EP2714050A1 (en) * 2011-06-03 2014-04-09 Elan Pharmaceuticals, Inc. Scyllo-inositol for the treatment of behavioral and psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303274D0 (sv) * 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
IL108595A (en) * 1994-02-08 1998-09-24 Yissum Res Dev Co History of Carboxylic Acid 2,2,3,3 Tetramethyl Cyclophen (ACMT) (Process for their Preparation and Pharmaceutical Preparations Containing Them)
US6555585B2 (en) * 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
IL147953A (en) * 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-

Also Published As

Publication number Publication date
IL172134A (en) 2011-02-28
WO2004105746A1 (en) 2004-12-09
IL156203A0 (en) 2003-12-23
IL172134A0 (en) 2006-04-10
EP1626710A1 (en) 2006-02-22
JP2007500205A (ja) 2007-01-11
EP1626710B1 (en) 2008-10-01
US20070043122A1 (en) 2007-02-22
DE602004016841D1 (de) 2008-11-13
ATE409469T1 (de) 2008-10-15
US20100048721A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
Coant et al. Ceramidases, roles in sphingolipid metabolism and in health and disease
Shaltiel et al. Valproate decreases inositol biosynthesis
Gould et al. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
Quiroz et al. Molecular effects of lithium
Chalfant et al. The structural requirements for ceramide activation of serine-threonine protein phosphatases
Manji et al. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications
Müller et al. PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid.
Sassa et al. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells
Bielawska et al. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide.
Russo et al. Myristate-derived d16: 0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties
Vadnal et al. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate
Denisova et al. Vitamin K and sphingolipid metabolism: evidence to date
Jafurulla et al. Sphingolipids in the function of G protein-coupled receptors
US20120028921A1 (en) Methods and compositions using oxidized phospholipids
Gupta et al. Protective effect of resveratrol against intracortical FeCl3-induced model of posttraumatic seizures in rats
RU2268721C2 (ru) Способ выявления соединений, пригодных для лечения и/или профилактики ожирения
Carlin et al. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes
EP1626710B1 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP3568138B1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
JP2007501846A (ja) トコトリエノールの予防的使用および治療的使用
Strunecka et al. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us?
Obata et al. Histamine increases interstitial adenosine concentration via activation of ecto-5′-nucleotidase in rat hearts in vivo
Giménez et al. Cytidine (5′) diphosphocholine-induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats
Yun et al. Lysophosphatidylcholine suppresses apoptosis and induces neurite outgrowth in PC12 cells through activation of phospholipase D2
Hasham et al. Glutamate-mediated activation of protein kinase C in hippocampal neurons

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20120528